- Home
- HTD vs INBX Comparison
HTD vs INBX Comparison
Compare HTD & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HTD | INBX |
|---|---|---|
| Founded | N/A | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 899.3M | 999.7M |
| IPO Year | 2003 | 2024 |
Fundamental Metrics
Financial Performance| Metric | HTD | INBX |
|---|---|---|
| Price | $25.35 | $100.93 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $150.00 |
| AVG Volume (30 Days) | 50.4K | ★ 489.3K |
| Earning Date | 01-01-0001 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,300,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 550.00 |
| 52 Week Low | $22.40 | $12.80 |
| 52 Week High | $26.21 | $155.29 |
Technical Indicators
Market Signals| Indicator | HTD | INBX |
|---|---|---|
| Relative Strength Index (RSI) | 52.43 | 45.50 |
| Support Level | $24.28 | $99.20 |
| Resistance Level | $25.65 | $153.14 |
| Average True Range (ATR) | 0.36 | 13.75 |
| MACD | -0.04 | -3.93 |
| Stochastic Oscillator | 49.54 | 8.06 |
Price Performance
Historical ComparisonAbout HTD John Hancock Tax Advantaged Dividend Income Fund of Beneficial Interest
John Hancock Tax-advantaged Div Inc Fd is a closed-end, diversified management investment company. Its investment objective is to provide a high after-tax total return from dividend income and capital appreciation. The fund's portfolio composition consists of common stocks, preferred securities, corporate bonds, convertible bonds, and short-term investments. Its sector composition comprises utilities, financials, energy, communication services, materials, healthcare, real estate, consumer Staples, and short-term investments.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.